Related Experiment Video

Updated: Dec 20, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.1K

The renal antioxidative effect of losartan involves heat shock protein 70 in proximal tubule cells

Patricia G Vallés1,2, Victoria Bocanegra3, Valeria V Costantino3

  • 1Área de Fisiopatología, Departamento de Patología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina. pvalles@fcm.uncu.edu.ar.

Cell Stress & Chaperones
|May 25, 2020
PubMed

Insights

Losartan treatment enhances the protective heat shock protein 70 (HSP70) response in kidney cells of hypertensive rats, mitigating oxidative stress. This highlights HSP70

Area of Science:

  • Nephrology
  • Cardiovascular Research
  • Molecular Biology

Background:

  • Angiotensin II critically drives hypertension and kidney damage via AT1 receptors.
  • Local renin-angiotensin system (RAS) activity and intrarenal angiotensin II augment proximal tubular AT1 receptors.
  • NADPH oxidase activation, regulated by caveolin 1, is central to angiotensin II-induced kidney oxidative stress.

Purpose of the Study:

  • To investigate the role of heat shock protein 70 (HSP70) in regulating losartan-mediated antioxidative stress responses.
  • To examine the protective mechanisms of HSP70 in proximal tubule cells of spontaneously hypertensive rats (SHRs).

Main Methods:

  • Review of literature on renin-angiotensin system (RAS) activity in spontaneously hypertensive rats (SHRs).
  • Analysis of NADPH oxidase 4 (Nox4) expression and reactive oxygen species (ROS) production in kidney proximal tubules.
  • Examination of heat shock protein 70 (HSP70) synthesis and function in response to losartan treatment.

Main Results:

  • Angiotensin II upregulation induces oxidative stress in proximal tubules of SHRs, involving NADPH oxidase 4 (Nox4).
  • HSP70 acts as a molecular chaperone, critical for cellular recovery from stress and cytoprotection.
  • Losartan treatment's antioxidative effects are modulated by HSP70 in SHR proximal tubule cells.

Conclusions:

  • HSP70 plays a key role in mediating the antioxidative effects of losartan in the context of hypertension-induced kidney injury.
  • Targeting HSP70 may offer a therapeutic strategy to enhance renoprotection in hypertensive conditions.
  • Understanding HSP70 regulation is crucial for managing oxidative stress in kidney diseases associated with RAS activation.
Keywords:
Angiotensin IIHeat shock proteins 70 (HSP70)LosartanNox4 NADPH oxidaseRenal proximal tubule cells

More Related Videos

Intracellular Refolding Assay07:18

Intracellular Refolding Assay

Published on: January 24, 2012

14.6K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

844

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
801
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.2K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.1K
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
653
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
591